Cargando…

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzyżanowska, Natalia, Wojas-Krawczyk, Kamila, Milanowski, Janusz, Krawczyk, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950480/
https://www.ncbi.nlm.nih.gov/pubmed/35328510
http://dx.doi.org/10.3390/ijms23063087
_version_ 1784675150947418112
author Krzyżanowska, Natalia
Wojas-Krawczyk, Kamila
Milanowski, Janusz
Krawczyk, Paweł
author_facet Krzyżanowska, Natalia
Wojas-Krawczyk, Kamila
Milanowski, Janusz
Krawczyk, Paweł
author_sort Krzyżanowska, Natalia
collection PubMed
description Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area.
format Online
Article
Text
id pubmed-8950480
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89504802022-03-26 Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules? Krzyżanowska, Natalia Wojas-Krawczyk, Kamila Milanowski, Janusz Krawczyk, Paweł Int J Mol Sci Review Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monotherapy are anti-PD-1 and anti-PD-L1 antibodies. The effectiveness of both groups of antibodies has been proven in many clinical trials, which have translated into positive immunotherapeutic registrations for cancer patients worldwide. These antibodies are generally well tolerated, and certain patients achieve durable responses. However, given the resistance of some patients to this form of therapy, along with its other drawbacks, such as adverse events, alternatives are constantly being sought. Specifically, new drugs targeting already known molecules are being tested, and new potential targets are being explored. The aim of this paper is to provide an overview of the latest developments in this area. MDPI 2022-03-13 /pmc/articles/PMC8950480/ /pubmed/35328510 http://dx.doi.org/10.3390/ijms23063087 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Krzyżanowska, Natalia
Wojas-Krawczyk, Kamila
Milanowski, Janusz
Krawczyk, Paweł
Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
title Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
title_full Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
title_fullStr Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
title_full_unstemmed Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
title_short Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
title_sort future prospects of immunotherapy in non-small-cell lung cancer patients: is there hope in other immune checkpoints targeting molecules?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950480/
https://www.ncbi.nlm.nih.gov/pubmed/35328510
http://dx.doi.org/10.3390/ijms23063087
work_keys_str_mv AT krzyzanowskanatalia futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules
AT wojaskrawczykkamila futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules
AT milanowskijanusz futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules
AT krawczykpaweł futureprospectsofimmunotherapyinnonsmallcelllungcancerpatientsistherehopeinotherimmunecheckpointstargetingmolecules